Clover Health Investments Corp ((CLOV)) has held its Q2 earnings call. Read on for the main highlights of the call.

Claim 55% Off TipRanks

• Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
• Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks

Clover Health Investments Corp struck an upbeat tone in its latest earnings call, spotlighting rapid membership gains, surging revenue, and a clear path toward sustained profitability. Management acknowledged lingering risks around seasonality, litigation, and medical cost trends, but emphasized that improving unit economics and a stronger star rating are shifting the balance of evidence decisively in the company’s favor.

Explosive Membership Growth in Medicare Advantage

Average Medicare Advantage membership jumped 48% year over year to about 157,000 members in the second quarter of 2026, underscoring Clover’s growing footprint in a crowded market. The company now expects average membership of 156,000 to 158,000 for the full year, signaling confidence that recent enrollment gains are not a one‑off spike.

Revenue Surges on Scale and Enrollment Tailwinds

Total revenue reached $743 million in the second quarter, a 56% increase from a year earlier, driven primarily by the swelling member base and richer plan mix. For the first half of 2026, revenue climbed to roughly $1.5 billion, more than $550 million above the prior year, prompting management to lift full‑year guidance to a range of $2.92 billion to $3.0 billion.

Gross Profit Expansion and Growing Operating Leverage

Consolidated gross profit rose 54% year over year to $153 million in the second quarter, reflecting both higher scale and improving plan economics. Clover also reported that operating leverage expanded by more than 200 basis points, and it raised full‑year gross profit guidance to between $525 million and $555 million as fixed costs are spread over a larger revenue base.

Profitability Metrics Turn the Corner

The company delivered adjusted EBITDA of $41 million and GAAP net income of $28 million in the second quarter, marking a notable shift from its historically loss‑making profile. For the first half, adjusted EBITDA reached $81 million and GAAP net income totaled $55 million, leading Clover to increase full‑year adjusted EBITDA guidance to $70 million to $85 million and GAAP net income to $20 million to $35 million.

Balance Sheet Strength Enables Self‑Funded Growth

Clover ended the quarter with $443 million in cash and investments, no debt, and generated $133 million of operating cash flow in the first half of 2026, giving it ample liquidity. Management stressed that this balance sheet position supports the ability to self‑fund growth initiatives without turning to the capital markets, reducing financing risk for investors.

Star Rating Recalculation Boosts Strategic Flexibility

A recent court‑driven recalculation means all Medicare Advantage members are now in plans rated 4.5 stars for the 2027 payment year, a significant upgrade that enhances revenue potential and competitive positioning. While regulators have filed an appeal that keeps some legal uncertainty in play, Clover is already leveraging the higher rating to refine product design and bid strategy.

Cohort Maturation Driving Better Unit Economics

Management highlighted that newer member cohorts typically see about a $70 per‑member‑per‑month improvement in gross profit from year one to year two as care coordination and risk adjustment mature. The 2025 cohort represents roughly 21% of membership and the 2026 cohort about 28%, and both are said to be tracking in line with or ahead of expectations, setting up future margin expansion as these members age in.

Clinical and Operational Trends Show Favorable Momentum

Inpatient utilization trends, including those among first‑year members, are moving in a favorable direction and helping to stabilize medical costs. Outpatient trends, which peaked in March, have since moderated, while dental costs improved after claims management changes and Part D performance has benefited from better seasonal visibility.

SG&A Efficiency Reflects Scale Benefits

Adjusted SG&A totaled $112 million in the second quarter, representing 15% of revenue and an improvement of about 220 basis points year over year, even as membership nearly doubled versus 2024. This shift highlights the company’s ability to hold administrative spending in check as it grows, contributing to expanding margins and enhanced operating leverage.

Early‑Stage Membership Mix Keeps Pressure on Margins

A large share of Clover’s book remains in the first two years of its lifecycle, with the 2025 and 2026 cohorts together accounting for nearly half of total membership, and these early‑stage members tend to be less profitable. Management cautioned that this cohort mix will continue to weigh on near‑term margins until members progress to later years, where the economics historically improve.

Seasonality and Expected Fourth‑Quarter Headwinds

The company warned that its performance will not be linear, with management guiding to stronger consolidated gross profit in the third quarter than the fourth. While adjusted EBITDA is expected to remain positive in the third quarter, Clover anticipates returning to a typical seasonal loss in the fourth quarter due to higher costs related to the annual enrollment period and other seasonal medical trends.

Legal Overhang from Ongoing Litigation

Although Clover secured a favorable district court ruling that underpinned the 4.5‑star recalculation, regulators have filed a notice of intent to appeal, creating an overhang for the stock. The final outcome could affect future payments and plan economics, and management acknowledged that this legal process remains a key uncertainty for the business.

Monitoring Elevated Outpatient Trends

Outpatient utilization remains higher than in prior years despite recent moderation, and Clover is closely tracking this trend to avoid negative surprises in medical costs. The company also noted that its assumptions for 2027 do not rely on materially better trends than those of large national peers, suggesting a degree of prudence in its internal planning.

Expanding Clover Assistant Coverage Across Cohorts

Roughly two‑thirds of members are managed with Clover Assistant, the company’s clinical support platform, but coverage for the 2025 and 2026 cohorts in core markets like New Jersey and Georgia sits in the low 60s. Management sees room to raise this penetration, arguing that broader deployment should boost care coordination and further enhance cohort economics over time.

One‑Time Reserve Impact Skews Quarterly Comparisons

The first quarter included a one‑time adjustment tied to claims and an increase in incurred‑but‑not‑reported reserves, which inflated expense levels and introduced volatility in quarter‑to‑quarter comparisons. While management emphasized that these items are non‑recurring, investors are being urged to account for this distortion when analyzing SG&A and expense trends across the year.

Lack of Formal 2027 Guidance Leaves Some Questions

Despite expressing confidence in its trajectory, Clover declined to issue formal financial guidance for 2027, instead leaning on qualitative commentary around cohort maturation and the higher star rating. That restraint leaves some forward‑year specifics unquantified, and investors will likely wait for future updates to gauge how current momentum translates into longer‑term earnings power.

Upgraded 2026 Outlook Underpins Bullish Guidance

Clover’s raised full‑year 2026 outlook now calls for average Medicare Advantage membership of 156,000 to 158,000, revenue of $2.92 billion to $3.0 billion, gross profit of $525 million to $555 million, adjusted EBITDA of $70 million to $85 million, and GAAP net income of $20 million to $35 million. Management tied this more optimistic view to strong first‑half execution, robust cash generation, a debt‑free balance sheet, and the structural tailwinds from maturing cohorts and a stronger star rating, while still flagging third‑quarter strength and a seasonal fourth‑quarter dip.

Clover’s latest earnings call painted a picture of a company transitioning from high‑growth upstart to increasingly profitable operator, aided by scale, improving clinical performance, and a meaningful star rating upgrade. While legal disputes, elevated outpatient trends, and seasonal volatility remain watchpoints, the combination of rising guidance, solid cash reserves, and favorable cohort dynamics will likely keep the stock firmly on the radar of investors hunting for healthcare growth stories with a maturing profitability profile.